Skip to main content
    P

    Palvella Therapeutics, Inc (PVLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $144.60
    -7.88 (-5.17%)

    Market Cap: $2.23B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Palvella Therapeutics, Inc (PVLA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Palvella Therapeutics are Pharvaris BV (PHVS), Beam Therapeutics (BEAM) and Sarepta Therapeutics (SRPT). By market cap, Palvella Therapeutics ranks 5th of the 13 companies on this page; PTC Therapeutics (PTCT) is the largest at $5.30B.

    Peer Comparison

    PVLA's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Palvella Therapeutics (PVLA)$2.23BN/AN/A0.0%N/A0.0%0.00%
    Pharvaris BV (PHVS)$2.36BN/AN/A0.0%N/A0.0%0.00%
    Beam Therapeutics Inc (BEAM)$2.36BN/A15.0x-73.9%-29.7%-96.8%0.00%
    Sarepta Therapeutics Inc (SRPT)$1.72BN/A0.8x-5.9%-3.2%-4.5%0.00%
    Vera Therapeutics Inc (VERA)$2.03BN/A189.3x0.0%-83.0%0.0%0.00%
    PTC Therapeutics Inc (PTCT)$5.30BN/A5.2x-9.2%18.1%69.6%0.00%
    Ultragenyx (RARE)$1.64BN/A2.2x-71.8%N/A8.1%0.00%
    Harmony Biosciences Holdings (HRMY)$1.98B9.6x1.9x18.0%13.7%12.3%0.00%
    Septerna, Inc. Common Stock (SEPN)$2.03BN/A20.3x-61.3%N/A-12.2%0.00%
    Viridian Therapeutics Inc (VRDN)$3.51BN/A128.5x0.0%-41.8%-63.5%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    Replimune Group Inc (REPL)$2.08BN/AN/A0.0%-65.4%0.0%0.00%
    Precigen Inc (PGEN)$1.63B98.6x9.9x15.5%18.9%2438.0%0.00%
    Peer median$2.03B54.1x9.9x0.0%-16.5%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Palvella Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Pharvaris BV (PHVS)
    Pharvaris NV, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of rare disease therapies.
    PHVS competitors
    Beam Therapeutics Inc (BEAM)
    Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States.
    BEAM competitors
    Sarepta Therapeutics Inc (SRPT)
    Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapies, gene therapy...
    SRPT competitors
    Vera Therapeutics Inc (VERA)
    Vera Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immune diseases...
    VERA competitors
    PTC Therapeutics Inc (PTCT)
    PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for patients with rare disorders.
    PTCT competitors
    Ultragenyx (RARE)
    Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development...
    RARE competitors
    Harmony Biosciences Holdings (HRMY)
    Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and markets therapies for patients with rare neurological disorders.
    HRMY competitors
    Septerna, Inc. Common Stock (SEPN)
    Septerna, Inc. is a cutting-edge biotechnology firm dedicated to transforming disease treatment through its advanced selective protein modulation platform.
    SEPN competitors
    Viridian Therapeutics Inc (VRDN)
    Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients with serious illnesses.
    VRDN competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    Replimune Group Inc (REPL)
    Replimune Group, Inc., a biotechnology company, develops oncolytic immunogenic therapies to treat cancer. The company is headquartered in Woburn, Massachusetts.
    REPL competitors
    Precigen Inc (PGEN)
    Precigen, Inc. discovers and develops the next generation of cell and gene therapies in the United States. The company is headquartered in Germantown, Maryland.
    PGEN competitors

    Frequently Asked Questions About PVLA

    Who are Palvella Therapeutics' main competitors?

    The companies most similar to Palvella Therapeutics include Pharvaris BV (PHVS), Beam Therapeutics (BEAM), Sarepta Therapeutics (SRPT), Vera Therapeutics (VERA) and PTC Therapeutics (PTCT), listed from the closest match.

    Who is Palvella Therapeutics' biggest competitor?

    PTC Therapeutics (PTCT) is the largest of the similar companies at $5.30B; Pharvaris BV (PHVS) is the closest match by business profile, size, sector and industry.

    How does PVLA stock compare with its competitors?

    PVLA's net margin is 0.0% against a peer median of 0.0%.

    Which of Palvella Therapeutics' competitors pays a higher dividend?

    Palvella Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Palvella Therapeutics bigger than its competitors?

    No. Palvella Therapeutics is 5th by market cap among the 13 companies on this page; the largest is PTC Therapeutics (PTCT) at $5.30B.